Cargando…
A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV
BACKGROUND: The concentration and duration of antibodies (Ab) to SARS-CoV-2 infection predicts the severity of the disease and the clinical outcomes. Older people and those with HIV have impaired immune responses, worse outcomes after SARS-CoV-2 infection, and lower antibody responses after viral in...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940197/ https://www.ncbi.nlm.nih.gov/pubmed/35330585 http://dx.doi.org/10.3389/fmed.2022.768138 |
_version_ | 1784672877307494400 |
---|---|
author | Alcaide, Maria L. Nogueira, Nicholas F. Salazar, Ana S. Montgomerie, Emily K. Rodriguez, Violeta J. Raccamarich, Patricia D. Barreto, Irma T. McGaugh, Angela Sharkey, Mark E. Mantero, Alejandro M. Rodriguez, Allan E. Beauchamps, Laura Jones, Deborah L. |
author_facet | Alcaide, Maria L. Nogueira, Nicholas F. Salazar, Ana S. Montgomerie, Emily K. Rodriguez, Violeta J. Raccamarich, Patricia D. Barreto, Irma T. McGaugh, Angela Sharkey, Mark E. Mantero, Alejandro M. Rodriguez, Allan E. Beauchamps, Laura Jones, Deborah L. |
author_sort | Alcaide, Maria L. |
collection | PubMed |
description | BACKGROUND: The concentration and duration of antibodies (Ab) to SARS-CoV-2 infection predicts the severity of the disease and the clinical outcomes. Older people and those with HIV have impaired immune responses, worse outcomes after SARS-CoV-2 infection, and lower antibody responses after viral infection and vaccination. This study evaluated an Ab response to SARS-CoV-2 in people with HIV (PWH) and without HIV (HIV-) and its association with age. METHODS: A total of 23 COVID+PWH and 21 COVID+HIV- participants were followed longitudinally for 6 months post-mild COVID-19. Immunoglobin G (IgG) and immunoglobin M (IgM) Ab responses were measured by an in-house developed ELISA. Time points and HIV status interaction were analyzed using Poisson generalized estimating equations, and correlations were analyzed using non-parametric tests. RESULTS: Median age in PWH was 55 years with 28.6% women, while in the HIV- group was 36 years with 60.9% women. The mean time from COVID-19 diagnosis to study enrollment was 16 days for PWH and 11 days for HIV-. The mean CD4+ T-cell count/μl for PWH was 772.10 (±365.21). SARS-CoV-2 IgM and IgG were detected at all time points and Ab response levels did not differ by HIV status (p > 0.05). At entry, age showed a weak direct association with IgG responses (ρ = 0.44, p < 0.05) in HIV- but did not show any association in PWH. Similar associations between age, IgG, and HIV status emerged at day 14 (T1; ρ = 0.50, p < 0.05), 3 months (T3; ρ = 0.50, p < 0.05), and 6 months visit (T4; ρ = 0.78, p < 0.05) in the HIV- group. CONCLUSION: The Ab responses in the 6-month post-SARS-CoV-2 infection did not differ by HIV status, though a positive association was found between age and Ab response in older PWH. Results suggest that immune protection and vaccine responses are similar for PWH than for those without HIV infection. |
format | Online Article Text |
id | pubmed-8940197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89401972022-03-23 A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV Alcaide, Maria L. Nogueira, Nicholas F. Salazar, Ana S. Montgomerie, Emily K. Rodriguez, Violeta J. Raccamarich, Patricia D. Barreto, Irma T. McGaugh, Angela Sharkey, Mark E. Mantero, Alejandro M. Rodriguez, Allan E. Beauchamps, Laura Jones, Deborah L. Front Med (Lausanne) Medicine BACKGROUND: The concentration and duration of antibodies (Ab) to SARS-CoV-2 infection predicts the severity of the disease and the clinical outcomes. Older people and those with HIV have impaired immune responses, worse outcomes after SARS-CoV-2 infection, and lower antibody responses after viral infection and vaccination. This study evaluated an Ab response to SARS-CoV-2 in people with HIV (PWH) and without HIV (HIV-) and its association with age. METHODS: A total of 23 COVID+PWH and 21 COVID+HIV- participants were followed longitudinally for 6 months post-mild COVID-19. Immunoglobin G (IgG) and immunoglobin M (IgM) Ab responses were measured by an in-house developed ELISA. Time points and HIV status interaction were analyzed using Poisson generalized estimating equations, and correlations were analyzed using non-parametric tests. RESULTS: Median age in PWH was 55 years with 28.6% women, while in the HIV- group was 36 years with 60.9% women. The mean time from COVID-19 diagnosis to study enrollment was 16 days for PWH and 11 days for HIV-. The mean CD4+ T-cell count/μl for PWH was 772.10 (±365.21). SARS-CoV-2 IgM and IgG were detected at all time points and Ab response levels did not differ by HIV status (p > 0.05). At entry, age showed a weak direct association with IgG responses (ρ = 0.44, p < 0.05) in HIV- but did not show any association in PWH. Similar associations between age, IgG, and HIV status emerged at day 14 (T1; ρ = 0.50, p < 0.05), 3 months (T3; ρ = 0.50, p < 0.05), and 6 months visit (T4; ρ = 0.78, p < 0.05) in the HIV- group. CONCLUSION: The Ab responses in the 6-month post-SARS-CoV-2 infection did not differ by HIV status, though a positive association was found between age and Ab response in older PWH. Results suggest that immune protection and vaccine responses are similar for PWH than for those without HIV infection. Frontiers Media S.A. 2022-03-07 /pmc/articles/PMC8940197/ /pubmed/35330585 http://dx.doi.org/10.3389/fmed.2022.768138 Text en Copyright © 2022 Alcaide, Nogueira, Salazar, Montgomerie, Rodriguez, Raccamarich, Barreto, McGaugh, Sharkey, Mantero, Rodriguez, Beauchamps and Jones. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Alcaide, Maria L. Nogueira, Nicholas F. Salazar, Ana S. Montgomerie, Emily K. Rodriguez, Violeta J. Raccamarich, Patricia D. Barreto, Irma T. McGaugh, Angela Sharkey, Mark E. Mantero, Alejandro M. Rodriguez, Allan E. Beauchamps, Laura Jones, Deborah L. A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV |
title | A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV |
title_full | A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV |
title_fullStr | A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV |
title_full_unstemmed | A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV |
title_short | A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV |
title_sort | longitudinal analysis of sars-cov-2 antibody responses among people with hiv |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940197/ https://www.ncbi.nlm.nih.gov/pubmed/35330585 http://dx.doi.org/10.3389/fmed.2022.768138 |
work_keys_str_mv | AT alcaidemarial alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT nogueiranicholasf alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT salazaranas alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT montgomerieemilyk alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT rodriguezvioletaj alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT raccamarichpatriciad alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT barretoirmat alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT mcgaughangela alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT sharkeymarke alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT manteroalejandrom alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT rodriguezallane alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT beauchampslaura alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT jonesdeborahl alongitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT alcaidemarial longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT nogueiranicholasf longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT salazaranas longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT montgomerieemilyk longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT rodriguezvioletaj longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT raccamarichpatriciad longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT barretoirmat longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT mcgaughangela longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT sharkeymarke longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT manteroalejandrom longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT rodriguezallane longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT beauchampslaura longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv AT jonesdeborahl longitudinalanalysisofsarscov2antibodyresponsesamongpeoplewithhiv |